Antibodies capable of neutralizing Bourbon virus were detected in pooled plasma products collected from United States donors, according to a study in the Journal of Infectious Diseases, and their concentration showed a borderline significant increase over roughly two decades. European plasma pools were largely nonreactive.
That is a different kind of finding from a confirmed case report, and the distinction is the point. The result speaks to how many Americans have encountered the virus at some point, not to how many are getting sick. Only a handful of human Bourbon virus infections have ever been confirmed in the United States.
For families in the Lone Star tick's range, which stretches across the central, southern, and eastern states and into parts of the Northeast, the practical takeaway is narrow but timely. Late summer is peak season for tick contact, and a virus that produces mild or nonspecific illness in most people is exactly the kind that surveillance systems miss.
Antibody Signal in Pooled Plasma Points to Broader Contact
Scientists at Takeda Manufacturing in Austria used live virus neutralization testing to measure antibodies against Bourbon virus and related Thogotoviruses in pooled plasma-derived immunoglobulin collected in the United States and the European Union from 2006 to 2024.
None of the immunoglobulin lots contained detectable neutralizing antibodies against Thogotovirus or Dhorivirus. European preparations showed little reactivity. United States preparations, by contrast, carried Bourbon virus neutralizing antibodies at concentrations that edged upward over time, a trend the authors describe as borderline significant rather than firmly established.
The authors noted that only a few human cases have been confirmed while small studies suggest roughly 1 percent of people may have been exposed, and they warned that as climate change expands tick habitats, "these viruses may spread into new regions." As CIDRAP summarized the work, the researchers argue the illness is underrecognized because it often causes only mild or nonspecific symptoms and occurs primarily in rural areas with limited surveillance.
An accompanying editorial by Michael Busch and colleagues at the Vitalant Research Institute in San Francisco makes a broader argument: routinely screening donor-derived plasma products could speed identification of pathogens circulating in a population and give agencies an earlier read on population immunity than clinical case counts allow.
Confirmed Cases Remain Few, and the Distinction Matters
A disease becoming more common and a disease becoming better detected are not the same thing; this study measures the latter. Antibody prevalence indicates that immune systems have encountered the virus. It does not tell you when, where, how sick anyone became, or whether true incidence is rising.
Bourbon virus was first isolated in 2014 from a patient in Bourbon County, Kansas, who later died, and it has since been tied primarily to the Lone Star tick. Confirmed human cases have been reported in a small number of states, including Kansas, Oklahoma, and Missouri. Separately, CDC researchers identified neutralizing antibodies in North Carolina patients, concluding then that infections are likely more common than recognized. The new plasma work points in the same direction using a different sample.
MedicalDaily previously reported on New York's first confirmed Bourbon virus case, an article focused on one patient, the difficulty of diagnosis and the absence of a vaccine or specific antiviral treatment. That reporting described a single confirmed infection. The new development shifts the question from a single household to a population-level estimate of exposure and strengthens the argument that current case counts undercount reality.
Industry Funding and the Gaps the Study Leaves Open
The research team is based at Takeda Manufacturing Austria, part of a pharmaceutical company that manufactures plasma-derived immunoglobulin products. That relationship should be visible to readers. It cuts in an unusual direction here: the authors reported that the antibody levels found were not sufficient to support the use of immunoglobulin to prevent or treat Bourbon virus infection, a conclusion that does not favor the sponsor's product line.
Several limitations remain. Pooled plasma cannot be traced to individual donors, so the geographic distribution of exposure is unknown. The increase over time is borderline, not conclusive. Neutralizing antibodies can cross-react across related viruses, and no confirmed case count anchors the estimate. Whether any of this changes clinical testing practice is undecided, and no regulator or health agency has issued new guidance in response.
Peak Lone Star Tick Season Raises the Practical Stakes
None of this changes what a household should do, but it does raise the value of doing it. There is no vaccine for Bourbon virus and no specific antiviral treatment, so prevention and prompt medical attention carry the entire burden.
Bourbon virus illness typically begins with fever, fatigue, muscle and joint aches, headache, nausea and sometimes a rash, usually within a week or two of a tick bite. It can look like Lyme disease or a summer flu. The clinical warning sign is a tick exposure followed by fever that does not improve on doxycycline, the antibiotic used for bacterial tick-borne infections. Severe illness has occurred mainly in older adults and people with weakened immune systems.
Practical prevention is unglamorous and effective: EPA-registered repellent on skin, permethrin-treated clothing for people who work or hike in brush, and a full-body tick check after every outdoor session, which MedicalDaily has outlined in detail. Promptly removing an attached tick with fine-tipped tweezers remains the single highest-value step.
Anyone who develops fever, severe headache, confusion, or a rapidly worsening illness after a tick bite should seek medical care and mention the exposure explicitly. Routine Bourbon virus testing is not available at most commercial labs and is generally handled through state health departments or the CDC. MedicalDaily will monitor for expanded surveillance, additional confirmed cases, and any change in testing guidance.
Key Questions Answered
What is genuinely new in this report? Researchers detected Bourbon virus neutralizing antibodies in pooled United States plasma products collected from 2006 through 2024, with concentrations rising slightly over time. European pools were largely nonreactive.
Does this mean Bourbon virus cases are rising? Not necessarily. The study measures past exposure, not current incidence. It supports the view that infections are underrecognized rather than showing that more people are becoming ill.
How is Bourbon virus spread? Through the bite of an infected Lone Star tick. It is not spread between people. The tick is common across the central, southern, and eastern United States and is established in parts of the Northeast.
What are the symptoms? Fever, fatigue, muscle and joint aches, headache, nausea, and sometimes a rash, typically within one to two weeks of a bite. Severe illness has occurred mainly in older adults and people with weakened immune systems.
Is there a vaccine or treatment? No. There is no vaccine and no specific antiviral therapy. Care is supportive, which makes prevention and early medical evaluation more important.
Should the funding source affect how readers weigh the findings? Readers should know the authors work for a pharmaceutical manufacturer of plasma-derived products. The team reported that the antibody levels found were too low to support therapeutic use, a conclusion that does not advantage that product line.
What should someone do after a tick bite? Remove the tick promptly with fine-tipped tweezers, note the date, and watch for fever or worsening illness. Contact a clinician if symptoms appear, and mention the tick exposure directly.
